Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 7/20 | 0.46 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | UGCG | Q16739 | 1/20 | 0.41 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4728877 | 0.95 | L3MBTL1 (0.62) | L3MBTL1TDP1IDO1AGXTCA1 | |
| SCHEMBL16727734 | 0.93 | L3MBTL1 (0.65) | L3MBTL1TDP1IDO1AGXTCA1 | |
| SCHEMBL27089918 | 0.93 | L3MBTL1 (0.65) | L3MBTL1TDP1IDO1AGXTCA1 | |
| SCHEMBL1355360 | 0.93 | L3MBTL1 (0.65) | L3MBTL1TDP1IDO1AGXTCA1 | |
| SCHEMBL1427941 | 0.89 | TDP1 (0.54) | L3MBTL1TDP1IDO1AGXTCA1 | |
| SCHEMBL15233070 | 0.85 | TDP1 (0.63) | L3MBTL1TDP1IDO1AGXTCA1 | |
| SCHEMBL8499580 | 0.84 | IDO1 (0.61) | L3MBTL1TDP1IDO1AGXTCA1 | |
| SCHEMBL7228686 | 0.84 | TDP1 (0.50) | L3MBTL1TDP1IDO1CALM1MAOB | |
| SCHEMBL30565724 | 0.82 | L3MBTL1 (0.56) | L3MBTL1TDP1IDO1AGXTCA1 | |
| SCHEMBL9022493 | 0.81 | L3MBTL1 (0.59) | L3MBTL1TDP1IDO1AGXTCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360163-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2024-10-31 | — | — | US | disclosed |
| US-12049474-B2 | Nucleoside prodrugs and uses related thereto | EMORY UNIVERSITY (US) | 2024-07-30 | — | — | US | disclosed |
| WO-2024008941-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2024-01-11 | — | — | WO | disclosed |
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2022-09-22 | — | — | US | disclosed |
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2022-09-22 | — | — | US | disclosed |
| EP-4017499-A1 | NUCLEOSIDE PRODRUGS AND USES RELATED THERETO | Emory University (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-114502172-A | Nucleoside prodrugs and related uses thereof | 爱默蕾大学 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021035214-A1 | NUCLEOSIDE PRODRUGS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2021-02-25 | — | — | WO | disclosed |
| WO-2007096261-A2 | PROCESS FOR THE PREPARATION OF DIOXANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-30 | — | — | WO | disclosed |
| US-20070197615-A1 | Process for the preparation of the PPAR alpha agonist NS-220 | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| EP-1144408-A1 | SUBSTITUTED 1-(PIERIDIN-4-YL)-3-(ARYL) ISOTHIOUREAS THEIR PREPARATION AND THERAPEUTIC APPLICATION | PIERRE FABRE MEDICAMENT (FR) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000043391-A1 | SUBSTITUTED 1-(PIERIDIN-4-YL)-3-(ARYL) ISOTHIOUREAS THEIR PREPARATION AND THERAPEUTIC APPLICATION | PIERRE FABRE MEDICAMENT (FR) | 2000-07-27 | — | — | WO | disclosed |
| CN-1044911-C | Process for preparing prodrug | IGEN INC (US) | 1999-09-01 | — | — | CN | disclosed |
| CN-1217335-A | Method for preparing precursor medicine | IGEN INC (US) | 1999-05-26 | — | — | CN | disclosed |
| EP-0746336-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0746336-A4 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN INC (US) | 1996-07-26 | — | — | EP | disclosed |
| US-5296492-A | Certain chroman derivatives useful for treating symptoms caused by contraction of smooth muscles, circulatory diseases or epilepsy | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1994-03-22 | — | — | US | disclosed |
| CN-1070409-A | Prodrugs activated by targetted catalytic proteins | IGEN INC (US) | 1993-03-31 | — | — | CN | disclosed |
| WO-1993002703-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1993-02-18 | — | — | WO | disclosed |
| EP-0518342-A1 | Chroman derivatives | Nippon Kayaku Kabushiki Kaisha (JP) | 1992-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | PNPO, GSTO1, CYP2C18 | L3MBTL1 4216/4885TDP1 1205/4885IDO1 1110/4885 |
| US-20240360163-A1 | Nucleoside Prodrugs and Uses Related Thereto | PNPO, GSTO1, CYP2C18 | L3MBTL1 4216/4885TDP1 1205/4885IDO1 1110/4885 |
| US-12049474-B2 | Nucleoside prodrugs and uses related thereto | PNPO, GSTO1, CYP2C18 | L3MBTL1 4216/4885TDP1 1205/4885IDO1 1110/4885 |
| US-20070197615-A1 | Process for the preparation of the PPAR alpha agonist NS-220 | PPARD, PPARA, PPARG | L3MBTL1 4870/4885TDP1 4281/4885IDO1 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.